Gangliosides in vivo reduce diabetes incidence in non-obese diabetic mice.
Non-obese diabetic mice were treated daily with a mixture of gangliosides from day 30 until day 250 of life or until the mice became diabetic. Ganglioside treatment reduced diabetes incidence from 80-90% to 47% and from 20-30% to zero in female and male mice respectively. Gangliosides did not affect the frequency of perivasculitis. It is concluded that gangliosides can reduce diabetes incidence in non-obese diabetic mice.
Wilberz
S
S
Diabetes Research Institute, University of Düsseldorf, FRG.
Herberg
L
L
Renold
A E
AE
D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D003520:Cyclophosphamide / Q000494:pharmacology; D003921:Diabetes Mellitus, Experimental / Q000235:genetics / Q000517:prevention & control*; D005260:Female; D005732:Gangliosides / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008817:Mice, Mutant Strains; D012016:Reference Values
D001786:Blood Glucose; D005732:Gangliosides; D003520:Cyclophosphamide